Co-Chairs
Membership for the Phase I effort – Co-chairs Weili He, Martin Ho
|
Industry
|
Affiliation
|
Academic/FDA
|
Affiliation
|
|
Jie Chen
Yixin Fang
Doug Faries
Weili He 1
Qi Jiang
Kwan Lee 2
Xiwu Lin
Zhaoling Meng
Yang Song
Hongwei Wang
Roseann White
Richard Zink
|
Overland Pharma
AbbVie
Eli Lily
AbbVie
Seattle Genetics
Janssen
Janssen
Sanofi
Vertex Pharma. Inc.
AbbVie
The Third Opinion
Target Pharma. Solution
|
Ben Goldstein
Martin Ho 2
Telba Irony
Hana Lee
Mark Levenson 1
Pallavi Mishra-Kalyani
Frank Rockhold
Mark van der Laan
Tingting Zhou
|
Duke
FDA-CBER
FDA-CBER
FDA-CDER
FDA-CDER
FDA-CDER
Duke
UC Berkeley
FDA-CBER
|
1 Co-leads of Workstream #1; 2 Co-leads of Workstream #2
† Liz Stuart (Johns Hopkins University) participates as non-member
Membership for the Phase II effort – Co-chairs Weili He, Martin Ho
|
Industry
|
Affiliation
|
Academic/FDA
|
Affiliation
|
|
Jie Chen 1
Li Chen
Liang Fang
Yixin Fang 3
Doug Faries
Susan Gruber
Weili He 2
Xiwu Lin
Telba Irony
Tricia Luhn
Zhaoling Meng
Herb Pang
Yang Song
Hongwei Wang
|
Overland Pharma
Amgen
MyoKardia
AbbVie
Eli Lily
Putnam Data Sci
AbbVie
Janssen
Janssen
Genentech
Sanofi
Genentech
Vertex Pharma. Inc.
AbbVie
|
Ben Goldstein
Sai Dharmarajan
Martin Ho 3
Hana Lee 1
Mark Levenson 2
Heng Li
Pallavi Mishra-Kalyani
Frank Rockhold
Mark van der Laan
John Scott
Tingting Zhou
|
Duke
FDA-CDER
FDA-CBER
FDA-CDER
FDA-CDER
FDA-CDRH
FDA-CDER
Duke
UC Berkeley
FDA-CBER
FDA-CBER
|
1 Co-leads of Team #1; 2 Co-leads of Team #2; 3 Co-leads of Team #3
Membership for the Phase III effort - Co-chairs: Jie Chen, Yixin Fang, and Hana Lee
|
Industry
|
Affiliation
|
Academic/FDA
|
Affiliation
|
|
Jie Chen2,3
|
Overland Pharma
|
Peng Ding
|
UC Berkeley
|
|
Nadia Daizadeh
|
Novartis
|
Jennifer Kirk |
FDA |
|
Junrui Di
|
Pfizer
|
Mark van der Laan
|
UC Berkeley
|
|
Yixin Fang1
|
AbbVie
|
Joo-Yeon Lee
|
FDA
|
|
Doug Faries
|
Eli Lilly
|
Hana Lee1,3
|
FDA
|
|
Susan Gruber
|
Putman Data Science
|
Shiowjen Lee |
FDA |
|
Weili Hea
|
AbbVie
|
Mark Levensona
|
FDA
|
|
Thomas Jemielita
|
Merck
|
Ying Lu
|
Stanford
|
| Herb Pang |
Genentech |
Pallavi Mishra-Kalyani
|
FDA
|
|
Mingyang Shan
|
Eli Lilly
|
Lei Nie2
|
FDA
|
|
Yang Song
|
Vertex
|
Andrew Potter
|
FDA
|
|
Haijun Tian
|
Novartis
|
Frank Rockhold
|
Duke
|
|
Hongwei Wang
|
AbbVie
|
Yuan Li Shen |
FDA |
|
Xiang Zhang
|
CSL Behring
|
Roy Tamura
|
U. of S. Florida
|
|
Jing Zhao
|
Merck
|
Yan Wang
|
FDA
|
|
Yihua Zhao
|
Flatiron Health
|
Shu Yang
|
NCSU
|
|
|
|
Tingting Zhou
|
FDA
|
1: Co-leads for subteam 1; 2: Co-leads for subteam 2; 3: Co-lead for subteam 3; a: Advisory role.
Membership for the Phase IV effort - Co-chairs: Hana Lee, Hongwei Wang and Shu Yang
|
Industry
|
Affiliation
|
Academic/FDA
|
Affiliation
|
|
Xiang Zhang1
|
CSL Behring
|
Shu Yang1
|
NCSU
|
|
Ran Duan
|
Vertex
|
Pallavi Mishra-Kalyani
|
FDA
|
|
Yixin Fang
|
AbbVie
|
Jianjin Xu
|
FDA
|
|
Rima Izem
|
Novartis
|
Lei Nie
|
FDA
|
|
Birol Emir
|
Pfizer
|
Mark van der Laan
|
UC Berkeley
|
|
Herb Pang
|
Genentech
|
Yuan Ying
|
MD Anderson
|
|
Chenguang Wang
|
Regeneron
|
Peng Yang
|
MD Anderson
|
|
Weili Hea
|
AbbVie
|
Ke Zhu
|
Duke & NCSU
|
|
Demissie Alemayehu2
|
Pfizer
|
Mark Levensona
|
FDA
|
|
Zhaoling Meng
|
Sanofi
|
Hana Lee2
|
FDA
|
|
Tristan Naumann
|
Microsoft
|
Hussein Ezzeldin
|
FDA
|
|
Hongwei Wang3
|
AbbVie
|
Spencer Haupert
|
FDA
|
|
Kaijie Pan
|
Pfizer
|
Sue-Jane Wang
|
FDA
|
|
Tu Xu
|
Novo Nordisk
|
Gabriel Innes
|
FDA
|
|
Binbing Yu
|
AstraZeneca
|
Yong Chen
|
U Penn
|
|
Haitao Chu
|
Pfizer
|
Frank Rockhold
|
Duke
|
|
Susan Gruber
|
Targeted ML Solutions
|
Nikki Freeman
|
Duke
|
|
Cindy Lu
|
Astrazeneca
|
Gilmer Valdes
|
Moffitt Cancer Center
|
|
Haijun Tian
|
Eli Lilly
|
Alexej Gossman
|
Mayo Clinic
|
|
|
|
Sky Qiu
|
UC Berkely
|
|
|
|
Yun Lu3
|
FDA
|
|
|
|
Richard Forshee
|
FDA
|
|
|
|
Yong Ma
|
FDA
|
|
|
|
Fang Tian
|
FDA
|
|
|
|
Kendrick Li
|
St Jude Children’s
|
|
|
|
Xu Shi
|
U Michigan
|
1: Co-leads for Team 1; 2: Co-leads for Team 2; 3: Co-lead for Team 3; a: Advisory role.